Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
Metrics: PDF 660 views | Full Text 939 views | ?
Vijay Patil1,7,*, Amit Joshi1,7,*, Vanita Noronha1,7, Vivek Agarwala1,7, Anuradha Chougule1,7, Sadhana Kanan2,7, Atanu Bhattacharjee3,7, Arun Chandrasekharan1,7, Nikhil Pande1,7, Vijai Simha1,7, Supriya Goud1,7, Sucheta More1,7, Rajiv Kumar4,7, Abhishek Mahajan5,7, Amit Janu5,7, Nilendu Purandare6,7 and Kumar Prabhash1,7
1 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
2 Department of Biostatistics, Advanced Center for Treatment, Research, and Education in Cancer, Mumbai, India
3 Section of Biostatistics, Centre for Cancer Epidemiology, Tata Memorial Hospital, Mumbai, India
4 Department of Pathology, Tata Memorial Hospital, Mumbai, India
5 Department of Radiology, Tata Memorial Hospital, Mumbai, India
6 Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, India
7 Homi Bhabha National Institute, Mumbai, India
* These authors contributed equally to this work
Keywords: maintenance; pemetrexed; erlotinib; NSCLC
Received: February 04, 2019 Accepted: August 29, 2019 Published: October 29, 2019
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.